ArticleFrontiers in genetics2026
Identifying mitochondrial genes and potential biological functions in pre-eclampsia: bioinformatics and experimental insights.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pre-eclampsia (PE) is a specific type of gestational hypertension associated with high morbidity and mortality. This study aims to identify mitochondria-related regulatory molecules in PE through bioinformatics analysis, which will help pinpoint potential therapeutic targets and elucidate potential mechanisms of action in PE. Methods: This study integrated three PE placental transcriptome datasets (n = 103/157) to screen for mitochondrial-related hub genes. Key gene screening was performed by combining three machine learning algorithms-Random Forest, LASSO, and SVM-followed by the construction of a diagnostic neural network model. Additionally, single-cell sequencing data were utilized to analyze the cellular expression patterns of candidate genes in the placenta. To further elucidate the underlying mechanisms, functional validation was conducted both in PE rat model and Results: Machine learning analysis identified three key genes (GCLM, SNAP23, RHOT2), and the diagnostic model built upon them demonstrated excellent performance (training set AUC = 0.907; validation set AUC = 0.875). Single-cell analysis revealed the expression patterns of these genes within specific cell subtypes, consistent with the transcriptional features of trophoblast cell populations. In the PE rat model, downregulation of GCLM and SNAP23 and upregulation of RHOT2 were significantly correlated with clinical phenotypes such as hypertension and proteinuria, as well as changes in placental inflammatory factor levels (TNF-α, IL-1β, IL-6). Specifically, SNAP23 and GCLM showed negative correlations with inflammatory cytokines but positive correlations with fetal weight, while RHOT2 expression positively correlated with disease severity. Conclusion: This study establishes GCLM, SNAP23, and RHOT2 as mechanistically important biomarkers for preeclampsia. Among them, modulation of SNAP23 shows therapeutic potential in alleviating mitochondrial damage and inflammatory responses in PE, providing a new direction for intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.